GT BIOPHARMA, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable
GT BIOPHARMA, INC. (GTBP) had Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable of 45.00 thousand shares as of 2024-10-17, per its 10-K filed 2025-02-21.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions · last filed 2025-02-21
- 2024-10-17: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 45.00K shares.
- 2024-03-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 123.49K shares.
- 2023-09-30: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 2.83M shares.
- 2023-06-30: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 2.18M shares.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable |
|---|---|
| 2024-10-17 | 45.00K shares 10-K · filed 2025-02-21 |
| 2024-03-31 | 123.49K shares 10-Q · filed 2024-05-15 |
| 2023-09-30 | 2.83M shares 10-Q · filed 2023-11-01 |
| 2023-06-30 | 2.18M shares 10-Q · filed 2023-08-07 |
| 2023-05-31 | 1.60M shares 10-K · filed 2025-02-21 |
| 2023-05-15 | 150.00K shares 10-Q · filed 2024-11-14 |
| 2023-03-31 | 1.87M shares 10-Q · filed 2023-05-15 |
| 2023-01-31 | 1.60M shares 10-K · filed 2025-02-21 |
| 2023-01-27 | 1.40M shares 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |